Farit A. Khabirov

Kazan, TA, Russian Federation

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 27 publications

Myoadaptive overload syndromes of lower extremities in multiple sclerosis patients

Myoadaptive overload syndromes of lower extremities in multiple sclerosis patients

Journal: Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova

Published: August 08, 2025

Features of the clinical course of multiple sclerosis as a factor in persistent disability

Features of the clinical course of multiple sclerosis as a factor in persistent disability

Journal: Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova

Published: August 08, 2025

Long-term efficacy and safety of divozilimab during 2-year treatment of multiple sclerosis patients in randomized double-blind placebo-controlled clinical trial BCD-132-4/MIRANTIBUS

Long-term efficacy and safety of divozilimab during 2-year treatment of multiple sclerosis patients in randomized double-blind placebo-controlled clinical trial BCD-132-4/MIRANTIBUS

Journal: Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova

Published: April 27, 2024

Characteristics and dynamics of pathological changes in visual evoked potentials in multiple sclerosis

Characteristics and dynamics of pathological changes in visual evoked potentials in multiple sclerosis

Journal: Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova

Published: August 10, 2023

Efficacy and safety of antiCD20 monoclonal antibody divozilimab during 48-week treatment of multiple sclerosis patients in randomized double-blind placebo-controlled clinical trial BCD-132-4/MIRANTIBUS

Efficacy and safety of antiCD20 monoclonal antibody divozilimab during 48-week treatment of multiple sclerosis patients in randomized double-blind placebo-controlled clinical trial BCD-132-4/MIRANTIBUS

Journal: Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova

Published: August 10, 2023

Efficacy and safety of divozilimab during 24-week treatment of multiple sclerosis patients in randomized double-blind placebo-controlled clinical trial BCD-132-2

Efficacy and safety of divozilimab during 24-week treatment of multiple sclerosis patients in randomized double-blind placebo-controlled clinical trial BCD-132-2

Journal: Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova

Published: April 21, 2023

Long-term Efficacy and Safety of Sampeginterferon-β1a in the Treatment of Relapsing Remitting Multiple Sclerosis: a Randomized, Double-Blind Clinical Trial 104-Week Results

Long-term Efficacy and Safety of Sampeginterferon-β1a in the Treatment of Relapsing Remitting Multiple Sclerosis: a Randomized, Double-Blind Clinical Trial 104-Week Results

Journal: Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova

Published: February 27, 2023

New opportunities in the treatment of patients with multiple sclerosis (Resolution of the Council of Experts on April 23, 2022, Moscow, JSC «BIOCAD»)

New opportunities in the treatment of patients with multiple sclerosis (Resolution of the Council of Experts on April 23, 2022, Moscow, JSC «BIOCAD»)

Journal: Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova

Published: August 01, 2022

Differential diagnosis of multiple sclerosis in children

Differential diagnosis of multiple sclerosis in children

Journal: Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova

Published: August 01, 2022

Efficacy and safety of sampeginterferon β-1a in the treatment of relapsing remitting multiple sclerosis: results of 52 weeks of therapy in a randomized, double-blind clinical trial

Efficacy and safety of sampeginterferon β-1a in the treatment of relapsing remitting multiple sclerosis: results of 52 weeks of therapy in a randomized, double-blind clinical trial

Journal: Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova

Published: February 17, 2022

Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial.

Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial.

Journal: The Lancet. Neurology

Published: January 28, 2021

Comparison of the efficacy of Cellex and Cortexin in patients in the early recovery period of ischemic stroke

Comparison of the efficacy of Cellex and Cortexin in patients in the early recovery period of ischemic stroke

Journal: Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova

Published: January 15, 2021

Showing 1-12 of 27

Last Updated: 09/26/2026